462 related articles for article (PubMed ID: 29353886)
21. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
[No Abstract] [Full Text] [Related]
22. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
[TBL] [Abstract][Full Text] [Related]
23. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.
Liu Y; Azizian NG; Dou Y; Pham LV; Li Y
J Hematol Oncol; 2019 Nov; 12(1):119. PubMed ID: 31752970
[TBL] [Abstract][Full Text] [Related]
25. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.
Vandenberg CJ; Cory S
Blood; 2013 Mar; 121(12):2285-8. PubMed ID: 23341542
[TBL] [Abstract][Full Text] [Related]
26. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
27. The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression.
Wu Z; Hu Z; Han X; Li Z; Zhu Q; Wang Y; Zheng Q; Yan J
Biomed Pharmacother; 2017 Nov; 95():1574-1579. PubMed ID: 28950657
[TBL] [Abstract][Full Text] [Related]
28. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
29. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
30. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members.
Hogg SJ; Newbold A; Vervoort SJ; Cluse LA; Martin BP; Gregory GP; Lefebure M; Vidacs E; Tothill RW; Bradner JE; Shortt J; Johnstone RW
Mol Cancer Ther; 2016 Sep; 15(9):2030-41. PubMed ID: 27406984
[TBL] [Abstract][Full Text] [Related]
31. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
[TBL] [Abstract][Full Text] [Related]
32. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma.
Melchor J; Garcia-Lacarte M; Grijalba SC; Arnaiz-Leché A; Pascual M; Panizo C; Blanco O; Segura V; Novo FJ; Valero JG; Pérez-Galán P; Martinez-Climent JA; Roa S
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36854569
[TBL] [Abstract][Full Text] [Related]
33. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
Dunleavy K
Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
[TBL] [Abstract][Full Text] [Related]
34. The bromodomain and extra-terminal inhibitor CPI203 enhances the antiproliferative effects of rapamycin on human neuroendocrine tumors.
Wong C; Laddha SV; Tang L; Vosburgh E; Levine AJ; Normant E; Sandy P; Harris CR; Chan CS; Xu EY
Cell Death Dis; 2014 Oct; 5(10):e1450. PubMed ID: 25299775
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma.
Recasens-Zorzo C; Cardesa-Salzmann T; Petazzi P; Ros-Blanco L; Esteve-Arenys A; Clot G; Guerrero-Hernández M; Rodríguez V; Soldini D; Valera A; Moros A; Climent F; González-Barca E; Mercadal S; Arenillas L; Calvo X; Mate JL; Gutiérrez-García G; Casanova I; Mangues R; Sanjuan-Pla A; Bueno C; Menéndez P; Martínez A; Colomer D; Tejedor RE; Teixidó J; Campo E; López-Guillermo A; Borrell JI; Colomo L; Pérez-Galán P; Roué G
Haematologica; 2019 Apr; 104(4):778-788. PubMed ID: 29954928
[TBL] [Abstract][Full Text] [Related]
36. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas.
Mason KD; Vandenberg CJ; Scott CL; Wei AH; Cory S; Huang DC; Roberts AW
Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17961-6. PubMed ID: 19004807
[TBL] [Abstract][Full Text] [Related]
37. Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.
Fresquet V; Rieger M; Carolis C; García-Barchino MJ; Martinez-Climent JA
Blood; 2014 Jun; 123(26):4111-9. PubMed ID: 24786774
[TBL] [Abstract][Full Text] [Related]
38. MYC selects against reduced BCL2A1/A1 protein expression during B cell lymphomagenesis.
Sochalska M; Schuler F; Weiss JG; Prchal-Murphy M; Sexl V; Villunger A
Oncogene; 2017 Apr; 36(15):2066-2073. PubMed ID: 27694901
[TBL] [Abstract][Full Text] [Related]
39. The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells
Zhang Y; Zhou L; Bandyopadhyay D; Sharma K; Allen AJ; Kmieciak M; Grant S
Clin Cancer Res; 2019 Oct; 25(20):6195-6205. PubMed ID: 31358538
[TBL] [Abstract][Full Text] [Related]
40. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Landsburg DJ; Petrich AM; Abramson JS; Sohani AR; Press O; Cassaday R; Chavez JC; Song K; Zelenetz AD; Gandhi M; Shah N; Fenske TS; Jaso J; Medeiros LJ; Yang DT; Nabhan C
Cancer; 2016 Feb; 122(4):559-64. PubMed ID: 26565895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
